133 related articles for article (PubMed ID: 22337647)
1. Segmental chromosome aberrations converge on overexpression of mitotic spindle regulatory genes in high-risk neuroblastoma.
Ooi WF; Re A; Sidarovich V; Canella V; Arseni N; Adami V; Guarguaglini G; Giubettini M; Scaruffi P; Stigliani S; Lavia P; Tonini GP; Quattrone A
Genes Chromosomes Cancer; 2012 Jun; 51(6):545-56. PubMed ID: 22337647
[TBL] [Abstract][Full Text] [Related]
2. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
3. MYCN overexpression is associated with unbalanced copy number gain, altered nuclear location, and overexpression of chromosome arm 17q genes in neuroblastoma tumors and cell lines.
Kuzyk A; Booth S; Righolt C; Mathur S; Gartner J; Mai S
Genes Chromosomes Cancer; 2015 Oct; 54(10):616-28. PubMed ID: 26171843
[TBL] [Abstract][Full Text] [Related]
4. MYCN-mediated overexpression of mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival of tetraploid neuroblastoma cells.
Gogolin S; Batra R; Harder N; Ehemann V; Paffhausen T; Diessl N; Sagulenko V; Benner A; Gade S; Nolte I; Rohr K; König R; Westermann F
Cancer Lett; 2013 Apr; 331(1):35-45. PubMed ID: 23186832
[TBL] [Abstract][Full Text] [Related]
5. High-resolution detection and mapping of genomic DNA alterations in neuroblastoma.
Mosse YP; Greshock J; Margolin A; Naylor T; Cole K; Khazi D; Hii G; Winter C; Shahzad S; Asziz MU; Biegel JA; Weber BL; Maris JM
Genes Chromosomes Cancer; 2005 Aug; 43(4):390-403. PubMed ID: 15892104
[TBL] [Abstract][Full Text] [Related]
6. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
7. Novel risk stratification of patients with neuroblastoma by genomic signature, which is independent of molecular signature.
Tomioka N; Oba S; Ohira M; Misra A; Fridlyand J; Ishii S; Nakamura Y; Isogai E; Hirata T; Yoshida Y; Todo S; Kaneko Y; Albertson DG; Pinkel D; Feuerstein BG; Nakagawara A
Oncogene; 2008 Jan; 27(4):441-9. PubMed ID: 17637744
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
Alaminos M; Gerald WL; Cheung NK
Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
[TBL] [Abstract][Full Text] [Related]
9. Characterization of amplicons in neuroblastoma: high-resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes.
Fix A; Lucchesi C; Ribeiro A; Lequin D; Pierron G; Schleiermacher G; Delattre O; Janoueix-Lerosey I
Genes Chromosomes Cancer; 2008 Oct; 47(10):819-34. PubMed ID: 18553563
[TBL] [Abstract][Full Text] [Related]
10. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
11. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
[TBL] [Abstract][Full Text] [Related]
12. Focal DNA copy number changes in neuroblastoma target MYCN regulated genes.
Kumps C; Fieuw A; Mestdagh P; Menten B; Lefever S; Pattyn F; De Brouwer S; Sante T; Schulte JH; Schramm A; Van Roy N; Van Maerken T; Noguera R; Combaret V; Devalck C; Westermann F; Laureys G; Eggert A; Vandesompele J; De Preter K; Speleman F
PLoS One; 2013; 8(1):e52321. PubMed ID: 23308108
[TBL] [Abstract][Full Text] [Related]
13. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
Cetinkaya C; Martinsson T; Sandgren J; Träger C; Kogner P; Dumanski J; Díaz de Ståhl T; Hedborg F
BMC Cancer; 2013 May; 13():231. PubMed ID: 23656755
[TBL] [Abstract][Full Text] [Related]
14. Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas.
Westermann F; Muth D; Benner A; Bauer T; Henrich KO; Oberthuer A; Brors B; Beissbarth T; Vandesompele J; Pattyn F; Hero B; König R; Fischer M; Schwab M
Genome Biol; 2008 Oct; 9(10):R150. PubMed ID: 18851746
[TBL] [Abstract][Full Text] [Related]
15. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
16. Risk estimation of neuroblastoma patients using molecular markers.
Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma.
Alaminos M; Mora J; Cheung NK; Smith A; Qin J; Chen L; Gerald WL
Cancer Res; 2003 Aug; 63(15):4538-46. PubMed ID: 12907629
[TBL] [Abstract][Full Text] [Related]
18. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
19. Dissection of the oncogenic MYCN transcriptional network reveals a large set of clinically relevant cell cycle genes as drivers of neuroblastoma tumorigenesis.
Murphy DM; Buckley PG; Bryan K; Watters KM; Koster J; van Sluis P; Molenaar J; Versteeg R; Stallings RL
Mol Carcinog; 2011 Jun; 50(6):403-11. PubMed ID: 21557326
[TBL] [Abstract][Full Text] [Related]
20. Dickkopf-1 is down-regulated by MYCN and inhibits neuroblastoma cell proliferation.
Koppen A; Ait-Aissa R; Hopman S; Koster J; Haneveld F; Versteeg R; Valentijn LJ
Cancer Lett; 2007 Oct; 256(2):218-28. PubMed ID: 17643814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]